DAratumumab and REvlimid REfractory MM
NCT06541860 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2024-08-07
Summary
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Conditions
Sponsors & Collaborators
-
Fondazione IRCCS Policlinico San Matteo di Pavia
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-08-21
- Primary Completion
- 2028-02-21
- Completion
- 2028-08-21
Countries
- Italy
Study Locations
More Related Trials
-
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02116569 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT02076009 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
NCT03475628 ·Status: UNKNOWN ·Phase: PHASE2
-
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
NCT01615029 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex
NCT03180736 ·Status: COMPLETED ·Phase: PHASE3
-
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
NCT03837509 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT03746652 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03859427 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
NCT03091127 ·Status: COMPLETED
-
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06183489 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05160584 ·Status: RECRUITING
-
An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD
NCT01985126 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
NCT03111992 ·Status: COMPLETED ·Phase: PHASE1
-
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
NCT03871829 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03194867 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
NCT03143036 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
NCT03221634 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT03158688 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Dara-Pembro for Multiple Myeloma Patients
NCT04361851 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
NCT02206503 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02497378 ·Status: COMPLETED ·Phase: PHASE1
-
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
NCT02419118 ·Status: COMPLETED ·Phase: PHASE2/PHASE3